A citation-based method for searching scientific literature

Chad Bousman, Abdullah Al Maruf, Daniel J Müller. Curr Opin Psychiatry 2019
Times Cited: 37







List of co-cited articles
323 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena,[...]. Clin Pharmacol Ther 2015
469
48

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
J K Hicks, K Sangkuhl, J J Swen, V L Ellingrod, D J Müller, K Shimoda, J R Bishop, E D Kharasch, T C Skaar, A Gaedigk,[...]. Clin Pharmacol Ther 2017
246
45

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
John F Greden, Sagar V Parikh, Anthony J Rothschild, Michael E Thase, Boadie W Dunlop, Charles DeBattista, Charles R Conway, Brent P Forester, Francis M Mondimore, Richard C Shelton,[...]. J Psychiatr Res 2019
104
43

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
Chad A Bousman, Katarina Arandjelovic, Serafino G Mancuso, Harris A Eyre, Boadie W Dunlop. Pharmacogenomics 2019
77
37

Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
Paul Bradley, Michael Shiekh, Vishaal Mehra, Keith Vrbicky, Stacey Layle, Marilyn C Olson, Alejandra Maciel, Ali Cullors, Jorge A Garces, Andrew A Lukowiak. J Psychiatr Res 2018
77
32

Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
612
32

Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
Víctor Pérez, Ariana Salavert, Jordi Espadaler, Miquel Tuson, Jerónimo Saiz-Ruiz, Cristina Sáez-Navarro, Julio Bobes, Enrique Baca-García, Eduard Vieta, José M Olivares,[...]. BMC Psychiatry 2017
92
24


Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Elizabeth J Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J Müller, Henry M Dunnenberger, Wasun Chantratita, Barry Goldspiel, Yuan-Tsong Chen, Bruce C Carleton, Alfred L George,[...]. Clin Pharmacol Ther 2018
109
21

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
236
21

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
Chiara Fabbri, Katherine E Tansey, Roy H Perlis, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery,[...]. Eur Neuropsychopharmacol 2018
31
25

Commercial pharmacogenetic-based decision-support tools in psychiatry.
Chad A Bousman, Malcolm Hopwood. Lancet Psychiatry 2016
71
21



Contribution of common genetic variants to antidepressant response.
Katherine E Tansey, Michel Guipponi, Xiaolan Hu, Enrico Domenici, Glyn Lewis, Alain Malafosse, Jens R Wendland, Cathryn M Lewis, Peter McGuffin, Rudolf Uher. Biol Psychiatry 2013
123
18

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
18



A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.
Joel G Winner, Joseph M Carhart, C Anthony Altar, Josiah D Allen, Bryan M Dechairo. Discov Med 2013
113
18

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Kelly E Caudle, Katrin Sangkuhl, Michelle Whirl-Carrillo, Jesse J Swen, Cyrine E Haidar, Teri E Klein, Roseann S Gammal, Mary V Relling, Stuart A Scott, Daniel L Hertz,[...]. Clin Transl Sci 2020
169
18

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.
S G Leckband, J R Kelsoe, H M Dunnenberger, A L George, E Tran, R Berger, D J Müller, M Whirl-Carrillo, K E Caudle, M Pirmohamed. Clin Pharmacol Ther 2013
147
16

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.
Daniel K Hall-Flavin, Joel G Winner, Josiah D Allen, Joseph M Carhart, Brian Proctor, Karen A Snyder, Maureen S Drews, Linda L Eisterhold, Jennifer Geske, David A Mrazek. Pharmacogenet Genomics 2013
125
16

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.
Kelly E Caudle, Teri E Klein, James M Hoffman, Daniel J Muller, Michelle Whirl-Carrillo, Li Gong, Ellen M McDonagh, Katrin Sangkuhl, Caroline F Thorn, Matthias Schwab,[...]. Curr Drug Metab 2014
226
16

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.
Simona Volpi, Carol J Bult, Rex L Chisholm, Patricia A Deverka, Geoffrey S Ginsburg, Howard J Jacob, Melpomeni Kasapi, Howard L McLeod, Dan M Roden, Marc S Williams,[...]. Clin Pharmacol Ther 2018
66
16


Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Jacob T Brown, Jeffrey R Bishop, Katrin Sangkuhl, Erika L Nurmi, Daniel J Mueller, Jean C Dinh, Andrea Gaedigk, Teri E Klein, Kelly E Caudle, James T McCracken,[...]. Clin Pharmacol Ther 2019
67
16

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
Marin M Jukić, Tore Haslemo, Espen Molden, Magnus Ingelman-Sundberg. Am J Psychiatry 2018
63
16

Survey of US public attitudes toward pharmacogenetic testing.
S B Haga, J M O'Daniel, G M Tindall, I R Lipkus, R Agans. Pharmacogenomics J 2012
103
13

The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.
Andrea Gaedigk, Magnus Ingelman-Sundberg, Neil A Miller, J Steven Leeder, Michelle Whirl-Carrillo, Teri E Klein. Clin Pharmacol Ther 2018
183
13

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings.
Alejandra Maciel, Ali Cullors, Andrew A Lukowiak, Jorge Garces. Neuropsychiatr Dis Treat 2018
25
20

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
J K Hicks, J J Swen, C F Thorn, K Sangkuhl, E D Kharasch, V L Ellingrod, T C Skaar, D J Müller, A Gaedigk, J C Stingl. Clin Pharmacol Ther 2013
281
13

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
A John Rush, Madhukar H Trivedi, Stephen R Wisniewski, Andrew A Nierenberg, Jonathan W Stewart, Diane Warden, George Niederehe, Michael E Thase, Philip W Lavori, Barry D Lebowitz,[...]. Am J Psychiatry 2006
13


Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.
Chiara Fabbri, Joseph Zohar, Alessandro Serretti. Prog Neuropsychopharmacol Biol Psychiatry 2018
27
18


Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection.
Chad A Bousman, Heather Zierhut, Daniel J Müller. Clin Pharmacol Ther 2019
26
19

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
P C D Bank, K E Caudle, J J Swen, R S Gammal, M Whirl-Carrillo, T E Klein, M V Relling, H-J Guchelaar. Clin Pharmacol Ther 2018
115
13

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
C Hiemke, N Bergemann, H W Clement, A Conca, J Deckert, K Domschke, G Eckermann, K Egberts, M Gerlach, C Greiner,[...]. Pharmacopsychiatry 2018
366
13

Physicians' opinions following pharmacogenetic testing for psychotropic medication.
Lucas M Walden, Eva J Brandl, Amtul Changasi, Jessica E Sturgess, Alexander Soibel, Janna Fe D Notario, Sheraz Cheema, Nicole Braganza, Victoria S Marshe, Natalie Freeman,[...]. Psychiatry Res 2015
33
15

Pharmacogenetics of antidepressant response: A polygenic approach.
Judit García-González, Katherine E Tansey, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery, Tina Žagar,[...]. Prog Neuropsychopharmacol Biol Psychiatry 2017
45
10

Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.
S L Van Driest, Y Shi, E A Bowton, J S Schildcrout, J F Peterson, J Pulley, J C Denny, D M Roden. Clin Pharmacol Ther 2014
177
10

Frequency of CYP2D6 Alleles Including Structural Variants in the United States.
Andria L Del Tredici, Alka Malhotra, Matthew Dedek, Frank Espin, Dan Roach, Guang-Dan Zhu, Joseph Voland, Tanya A Moreno. Front Pharmacol 2018
54
10

Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial.
Lindsay S Elliott, John C Henderson, Moni B Neradilek, Nicolas A Moyer, Kristine C Ashcraft, Ranjit K Thirumaran. PLoS One 2017
79
10

Prediction of CYP2D6 phenotype from genotype across world populations.
Andrea Gaedigk, Katrin Sangkuhl, Michelle Whirl-Carrillo, Teri Klein, J Steven Leeder. Genet Med 2017
244
10

Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.
Stacey L Aldrich, Ethan A Poweleit, Cynthia A Prows, Lisa J Martin, Jeffrey R Strawn, Laura B Ramsey. Front Pharmacol 2019
39
10

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
M E E Shams, B Arneth, C Hiemke, A Dragicevic, M J Müller, R Kaiser, K Lackner, S Härtter. J Clin Pharm Ther 2006
159
10

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Thomas Rau, Gerlinde Wohlleben, Henrike Wuttke, Norbert Thuerauf, Jens Lunkenheimer, Mario Lanczik, Thomas Eschenhagen. Clin Pharmacol Ther 2004
147
10

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Madhukar H Trivedi, A John Rush, Stephen R Wisniewski, Andrew A Nierenberg, Diane Warden, Louise Ritz, Grayson Norquist, Robert H Howland, Barry Lebowitz, Patrick J McGrath,[...]. Am J Psychiatry 2006
10

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
J H Wang, Z Q Liu, W Wang, X P Chen, Y Shu, N He, H H Zhou. Clin Pharmacol Ther 2001
105
10

Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.
Kimberly Peterson, Eric Dieperink, Johanna Anderson, Erin Boundy, Lauren Ferguson, Mark Helfand. Psychopharmacology (Berl) 2017
34
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.